Open AccessEfficacy of leflunomide in the treatment of vasculitis
Author(s) -
Noura Mustapha,
Lillian Barra,
Simon Carette,
David Cuthbertson,
Nader Khalidi,
Curry L. Koening,
Carol A. Langford,
Carol A. McAlear,
Nataliya Milman,
Larry W. Moreland,
Paul A. Monach,
Philip Seo,
Ulrich Specks,
Antoine G. Sreih,
Steve Y Ytterberg,
Peter A. Merkel,
Christian Pagnoux
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/ve38dj
Subject(s) - medicine , granulomatosis with polyangiitis , leflunomide , microscopic polyangiitis , vasculitis , giant cell arteritis , tolerability , eosinophilic , discontinuation , population , gastroenterology , adverse effect , dermatology , pathology , disease , rheumatoid arthritis , environmental health
Only a few small case series, case reports, and one small clinical trial suggested some benefit of leflunomide (LEF) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and other vasculitides. We analysed the clinical efficacy and tolerability of LEF in a large cohort of patients with various vasculitides.